| Popis: |
Purpose: Teriparatide is an anabolic agent belonging to a new class of antiosteoporosis drugs. The Turkish Social Security Institution covers teriparatide for patients with osteoporosis who have 2 osteoporotic fractures, are older than 65 years, and have a T-score of less than -4. We evaluated possible secondary contributors to osteoporosis in patients referred for treatment with this agent. Material and Method: All patients referred to our center for teriparatide treatment over 2 year were evaluated for clinical risk factors for osteoporosis, medical history, and medications. Results: Sixty-eight patients (63 women and 5 men, mean age:71.3±9.4 (50-89 years) were referred. Twenty-nine patients (42.6%) had received osteoporosis therapy before referral, consisting of bisphosphonate (n=20), strontium ranelate (n=6), calcitonin (n=2), or calcitonin and bisphosphonate (n=1). The mean duration of the previous therapy was 46.4± 38.5 (3-120 months). In all, 50 of the 68 patients (73.5%), including all of the men, had a contributor to secondary osteoporosis. Vitamin D deficiency was the most frequent contributor in 34 patients (52.3%). Other common contributors were hyperthyroidism and hypogonadism. Only 3 of 18 patients with hyperthyroidism and none of the patients with hypogonadism had been diagnosed previously, and 16 of the 24 patients receiving vitamin D supplementation still had deficiency of this vitamin. Discussion: Most of our patients had a contributor to secondary osteoporosis, which often had not been identified previously. Identifying and correcting such disorders might improve the treatment of osteoporosis and reduce the risk of subsequent fracture. Turk Jem 2013; 17: 98-101 |
